

Lung Cancer Therapeutics: Market Research Report

<https://marketpublishers.com/r/LFDDCB1CDDDBEN.html>

Date: July 2009

Pages: 842

Price: US\$ 3,950.00 (Single User License)

ID: LFDDCB1CDDDBEN

Abstracts

This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US\$.

The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs.

The report provides separate comprehensive analytics for the US, Europe and Rest of World.

Annual forecasts are provided for each region for the period 2005 through 2015.

The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co.Ltd., Telik, Inc., and Woomera Therapeutics, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Chemotherapy Drugs
Targeted Drugs

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Lung Cancer Therapeutics – Driven by Next Generation Drugs
New Therapies Drive NSCLC Market
Market Value of Taxanes to Decrease by 2015
Lung Cancer – The Killer Disease
Lung Cancer – A Quick Glance at Global Statistics
Asia Heading for Possible Lung Cancer Epidemic

Table 1. Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart)

2. LUNG CANCER – AN INSIGHT

Lungs – Critical for Oxygen Supply
Lung Cancer – An Introduction
Common Symptoms of Lung Cancer
Types of Lung Cancer
Non-Small Cell Lung Cancer
NSCLC – At a Glance
Small Cell Lung Cancer
Risk Factors for Lung Cancer
Female Smokers at Higher Risk of Developing Lung Cancer
Lung Cancer Diagnostics

Lung Cancer Staging
Staging for Non-Small Cell Lung Cancer
Staging for Small Cell Lung Cancer

3. LUNG CANCER TREATMENT MODALITIES

Surgery
Radiation Therapy
Chemotherapy
Combination Therapy
Photodynamic Therapy
Vaccines
Common Treatment Modalities for SCLC and NSCLC Lung Cancers
Pain Management

4. INTRODUCTION TO LUNG CANCER THERAPEUTICS

Chemotherapy
Drug Administration
Overview of Chemotherapy Regimens and Drugs
Side Effects of Chemotherapy
Targeted Therapy
Chemotherapy Drugs for SCLC Treatment
Chemotherapy Drugs for NSCLC Treatment
Major Chemotherapy Drugs
Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic Name
Overview of Select Chemotherapeutic Drugs
Alimta
Carboplatin and Cisplatin
Docetaxel
Paclitaxel
Xyotax
Gemcitabine
Gefitinib
Irinotecan
Vinorelbine (Navelbine®)

5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS

R&D Focus in NSCLC Treatment

Drug Development Process – Growth Opportunities & Challenges

Product Pipeline for NSCLC Treatment

Product Pipeline for NSCLC Treatment

Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment

Companies Focus on Molecular Targeted Therapies

Molecular Targeted Therapies – Overview of Select Product Candidates

Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron

BIBW 2992 – Boehringer Ingelheim

Erbix (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb

Nexavar (sorafenib) - Bayer Schering

Recentin (cediranib) – AstraZeneca

Sutent (sunitinib) – Pfizer

Zactima (vandetanib) – AstraZeneca

Zolinza (vorinostat) – Merck & Co

Pipeline for Cytotoxic Therapy – Overview of Select Products

Abraxane (albumin-bound paclitaxel) - Abraxis

Glutoxim (NOV-002) - Novelos

Javlor (vinflunine) – Pierre Fabre

Lipoplatin (liposomal cisplatin) – Regulon

Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis

6. PRODUCT APPROVALS/INNOVATIONS/ LAUNCHES

Intas Biopharmaceuticals to Introduce Gefitinib in India

Celgene Receives FDA Fast Track Product Designation for Amrubicin

EMA Approves ALIMTA for First-Line Therapy of Advanced NSCLC

Celgene's Cancer Drug Receives Orphan Drug Status from European Commission

Alimta Receives FDA Approval

Roche Receives Approval from European Authorities for Avastin

OSI Pharmaceuticals Introduces Tarceva in Japan

Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer

Natco Pharma Unveils an Injectable Drug for Lung Cancer, Pemnat

Roche Scientific Introduces Tarceva in the Indian Market

GlaxoSmithKline's HYCAMTIN® Receives Marketing Approval from EC

Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment

UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug

Agennix's Talactoferrin Alfa Program Obtains Fast Track Designation from FDA

Novelos Therapeutics' NOV-002 Receives Fast Track Designation from FDA

7. RESEARCH & CLINICAL TRIALS

Novartis Commences Phase III Clinical Trial of ASA404

Results of BR.21 Trials

Genentech Announces Results of Phase III BETA Lung Trial

Results of SATURN Clinical Trial

Results of Zactima's Clinical Trials

Results of Erbitux's Phase III Trials

Results of Roche's AVAiL Clinical Trial

GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine

FASgen Announces Research Results of FAS093

The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine

Gemin X Commences Clinical Trials of GX15-070

Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs

OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva®

Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer Vaccine

University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine

Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of Picoplatin

Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595

Ligand Pharmaceuticals Tables Clinical Results of Targretin®

Bayer and Onyx Start Phase III Trial of Nexavar®

Abraxis Announces Clinical Results of ABRAXANE®

Introgen Conducts Phase II Clinical Trials of INGN 225

YM BioSciences Commences Clinical Trial of Nimotuzumab

8. RECENT INDUSTRY ACTIVITY

Merck Agrees to Merge with Shering-Plough

Abbott Molecular Signs Agreement with Genentech, OSI and Roche

IMUC Acquires Monoclonal Antibody Technology from MDC

Quest PharmaTech Enters into Collaboration with BC Cancer Agency

Daiichi Sankyo Acquires U3 Pharma

MacroGenics Takes Over Raven Biotechnologies

Roche Acquires Piramed

Bristol-Myers Squibb Acquires Kosan Biosciences

Point Therapeutics and DARA Biosciences Ink Merger Agreement

Celgene Acquires Pharmion

Pfizer to Takeover Serenex
ATS Acquires Majority Stake in GANYMED Pharmaceuticals
NCCN, AstraZeneca and Abraxis Enter into Collaboration
Eli Lilly Agrees to Take Over ImClone Systems
CytRx Takes Over Innovive Pharmaceuticals
Abbott Extends Discovery Partnership with Caprion
Bristol-Myers and ImClone to Expand the Clinical Development Program for ERBITUX
Biomoda and New Mexico Tech Enter into a Collaborative Agreement
Binex Inks Sponsored Research Agreement with MaxCyte
Sincere Pharmaceutical Acquires Master Luck
Dako Enters into Collaboration with OSI, Roche, and Genentech
Biomira and Merck Sign Revised Supply and Collaboration Agreements
ImClone Systems Terminates Development Agreement with UCB
Astellas Pharma's US Subsidiary Acquires Agensys
Antisoma Enters into an Agreement with Novartis
Pharmacyclics Files NDA for Xcytrin® Injection

9. FOCUS ON SELECT GLOBAL PLAYERS

AstraZeneca PLC (UK)
Bristol-Myers Squibb Co. (US)
Eli Lilly & Co. (US)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (US)
GlaxoSmithKline Plc (UK)
Novartis Pharmaceuticals Corporation (US)
OSI Pharmaceuticals, Inc. (US)
Sanofi-Aventis (France)
Companies with Pipeline Drugs
AbGenomics International Inc. (US)
ImClone Systems, Inc. (US)
Pfizer, Inc. (US)
Merck Serono International S.A. (Switzerland)
Merck & Co. Ltd. (US)
Telik, Inc. (US)
Woomera Therapeutics, Inc. (US)

10. GLOBAL MARKET PERSPECTIVE

Table 2. World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – US, Europe and Rest of World Independently Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

Table 3. World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – Percentage Breakdown of Annual Revenues for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. MARKET ANALYSIS

NSCLC Drug Market to Rise Sharply

Lung Cancer Prevalence

A Major Cause of Death among US Women

Statistics

Market Scenario

FDA Places New Restrictions on Iressa

Innovative Technology Enables Early Diagnosis of Lung Cancer

Avastin to Emerge as the Preferred NSCLC Drug in the US

Product Approvals/Clinical Trials/Introductions/ Launches

Strategic Corporate Developments

Key Players

B. MARKET ANALYTICS

Table 4. US Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Segment – Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

Table 5. US 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Segment – Percentage Breakdown of Annual Revenues for Chemotherapy Drugs and

Targeted Drugs Markets for Years 2006, 2009 & 2015

2. EUROPE

A. MARKET ANALYSIS

Lung Cancer Therapeutics Market to Witness Robust Growth
Product Approvals
Clinical Trials

B. MARKET ANALYTICS

Table 6. European Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Independently Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

Table 7. European 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2A.FRANCE

A. MARKET ANALYSIS

Overview of Lung Cancer Market
Key Player

B. MARKET ANALYTICS

Table 8. French Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2B.GERMANY

A. MARKET ANALYSIS

Lung Cancer Scenario
Chemotherapy Gains Preference
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 9. German Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2C.ITALY

A. MARKET ANALYSIS

Incidence in Women on Rise
Treatment

B. MARKET ANALYTICS

Table 10. Italian Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2D.THE UNITED KINGDOM

A. MARKET ANALYSIS

British Women at Higher Risk
Fast Facts
Proposed Cancer Care Improvements Mullied by British Government
NICE Recommends Use of Erlotinib in NSCLC Treatment
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 11. UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2E.REST OF EUROPE

A. MARKET ANALYSIS

Outlook
Strategic Corporate Developments
Key Player

B. MARKET ANALYTICS

Table 12. Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

3. REST OF WORLD

A. MARKET ANALYSIS

Australia
Fast Facts
Brazil
China
Overview of NSCLC Drug Market
India
Japan
Product Launches
Strategic Corporate Development

B. MARKET ANALYTICS

Table 13. Rest of World Recent Past, Current & Future Analysis for Non-Small Cell

Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US\$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)

Region/Country/Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

I would like to order

Product name: Lung Cancer Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/LFDDCB1CDDDBEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LFDDCB1CDDDBEN.html>